A phase I/II evaluation of oral L-2-oxothiazolidine-4-carboxylic acid in asymptomatic patients infected with human immunodeficiency virus

Patricia Barditch-Crovo, Dennis Noe, Gail Skowron, Michael Lederman, Robert C. Kalayjian, Peggy Borum, Rose Buier, W. Bruce Rowe, Dennis Goldberg, Paul Lietman

Research output: Contribution to journalArticlepeer-review

Abstract

A randomized double-blind, placebo-controlled study was conducted in 37 asymptomatic HIV-infected individuals (mean CD4 count 707 cells/mm3) to characterize the safety, pharmacokinetics, and effect on blood thiols of three dosage levels of a cysteine prodrug, L-2-oxothiazolidine-4-carboxylic acid (OTC; Procysteine; Clintec Technologies, Deerfield, IL). Single-dose administration of OTC resulted in measurable plasma levels at all dosages, with a mean peak plasma concentration of 734 ± 234 nmol/mL at the highest dosage studied. After 4 weeks of administration three times daily, a statistically significant increase was seen in whole blood glutathione in the 1,500 mg and 3,000 mg dose groups compared with the placebo group. A significant increase in whole blood cysteine and peripheral blood mononuclear cell (PBMC) glutathione was not seen during the study period.

Original languageEnglish (US)
Pages (from-to)357-363
Number of pages7
JournalJournal of clinical pharmacology
Volume38
Issue number4
DOIs
StatePublished - Apr 1998

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'A phase I/II evaluation of oral L-2-oxothiazolidine-4-carboxylic acid in asymptomatic patients infected with human immunodeficiency virus'. Together they form a unique fingerprint.

Cite this